Evaluation of Effects of Continuous Glucose Monitoring on Physical Activity Habits and Blood Lipid Levels in Persons With Type 1 Diabetes Managed With MDI: An Analysis Based on the GOLD Randomized Trial (GOLD 8).

blood lipids continuous glucose monitoring hypoglycemia low-grade inflammation physical activity

Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
08 Jun 2022
Historique:
entrez: 9 6 2022
pubmed: 10 6 2022
medline: 10 6 2022
Statut: aheadofprint

Résumé

People with type 1 diabetes generally view it easier to exercise when having continuous information of the glucose levels. We evaluated whether patients with type 1 diabetes managed with multiple daily insulin injections (MDI) exercised more after initiating continuous glucose monitoring (CGM) and whether the improved glycemic control and well-being associated with CGM translates into improved blood lipids and markers of inflammation. The GOLD trial was a randomized cross-over trial over 16 months where patients used either CGM or capillary self-monitoring of blood glucose (SMBG) over six months, with a four-month wash-out period between the two treatment periods. We compared grade of physical activity, blood lipids, apolipoproteins, and high-sensitivity C-reactive protein (hsCRP) levels during CGM and SMBG. There were 116 patients with information of physical activity estimated by the International Physical Activity Questionnaire (IPAQ) during both CGM and SMBG. No changes were found during CGM or SMBG, IPAQ scores 3305 versus 3878 ( Although many patients experience it easier to perform physical activity when monitoring glucose levels with CGM, it does not influence the amount of physical activity in persons with type 1 diabetes. Blood lipids, apolipoprotein, and hsCRP levels were similar during CGM and SMBG.

Sections du résumé

BACKGROUND UNASSIGNED
People with type 1 diabetes generally view it easier to exercise when having continuous information of the glucose levels. We evaluated whether patients with type 1 diabetes managed with multiple daily insulin injections (MDI) exercised more after initiating continuous glucose monitoring (CGM) and whether the improved glycemic control and well-being associated with CGM translates into improved blood lipids and markers of inflammation.
METHOD UNASSIGNED
The GOLD trial was a randomized cross-over trial over 16 months where patients used either CGM or capillary self-monitoring of blood glucose (SMBG) over six months, with a four-month wash-out period between the two treatment periods. We compared grade of physical activity, blood lipids, apolipoproteins, and high-sensitivity C-reactive protein (hsCRP) levels during CGM and SMBG.
RESULTS UNASSIGNED
There were 116 patients with information of physical activity estimated by the International Physical Activity Questionnaire (IPAQ) during both CGM and SMBG. No changes were found during CGM or SMBG, IPAQ scores 3305 versus 3878 (
CONCLUSION UNASSIGNED
Although many patients experience it easier to perform physical activity when monitoring glucose levels with CGM, it does not influence the amount of physical activity in persons with type 1 diabetes. Blood lipids, apolipoprotein, and hsCRP levels were similar during CGM and SMBG.

Identifiants

pubmed: 35677967
doi: 10.1177/19322968221101916
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19322968221101916

Auteurs

Thomas Nyström (T)

Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.

Erik Schwarz (E)

Department of Internal Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.

Sofia Dahlqvist (S)

Department of Medicine, NU-Hospital Group, Uddevalla, Sweden.
Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.

Magnus Wijkman (M)

Department of Internal Medicine and Department of Medical and Health Sciences, Linköping University, Norrköping, Sweden.

Magnus Ekelund (M)

Department of Clinical Sciences, Lund University, Lund, Sweden.

Helen Holmer (H)

Department of Internal Medicine, Centralsjukhuset, Kristianstad, Sweden.

Jan Bolinder (J)

Department of Medicine, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden.

Jarl Hellman (J)

Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University, Uppsala, Sweden.

Henrik Imberg (H)

Statistiska Konsultgruppen, Gothenburg, Sweden.
Department of Mathematical Sciences, Chalmers University of Technology and University of Gothenburg, Gothenburg, Sweden.

Irl B Hirsch (IB)

School of Medicine, University of Washington, Seattle, WA, USA.

Marcus Lind (M)

Department of Medicine, NU-Hospital Group, Uddevalla, Sweden.
Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Department of Internal Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.

Classifications MeSH